{
  "docId": "019de071-5aa5-74ef-a452-60fcbf49cdc6",
  "docSlug": "58255c61d2bdadc3239a5fe01efc41e1",
  "documentTitle": "BioNTech | Results Presentation Deck | 43 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 43,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a timeline-like visual representation for clinical phases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-5aa5-74ef-a452-60fcbf49cdc6/21",
  "deckHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6",
  "deckJsonHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6.json",
  "deckAnchorHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.72,
        "x": 0.04,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Planned randomized trial start in 2H 2021: CPI, checkpoint inhibitor; R/R, relapsed or refractory; Next-Gen, next generation; HPV, Human Papilloma Virus; FPD, first patient dosed; 1L, first-line; CRC, colorectal cancer; CAR, chimeric antigen receptor; CLDN6, Claudin-6",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67d4ed6b-d624-4dff-89c5-291e64c8820a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.92,
        "x": 0.04,
        "y": 0.315
      },
      "kind": "table",
      "text": "Table showing drug class, platform, candidate, indication, phase progress, and milestones.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9682d29-7677-4d75-9aeb-d8535bb18fb6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.19
      },
      "kind": "title",
      "text": "15 product candidates in 18 clinical trials",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a560a9e2-68b5-43b7-9ce2-b938270fd128",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.63,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "Oncology: Multiple Phase 2 Trials Starting in 2021",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73951283-ea16-491c-add1-193af74b1e9c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "830db282-49bf-400d-b140-b0ae57976e2f",
      "evidence": "table/data: Table showing drug class, platform, candidate, indication, phase progress, and milestones.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "6e4799c0-87d6-4e3e-8f59-acf7c6f9bbe5",
      "evidence": "The table uses horizontal bars to represent clinical trial phases over time.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 25,
      "from": 15,
      "beatId": "53c149a8-57e4-41f6-bcc6-f6d3b92e5c06",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The document presents BioNTech's product portfolio, including its COVID-19 vaccine and pipeline candidates",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 42,
      "from": 7,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6afc8369-9bbf-45e1-a77c-ba4d4e30b836",
      "evidence": "The document uses the Golden Circle framework to explain its vision, strategy, and achievements",
      "position": 0,
      "objective": "To explain why BioNTech's vision and strategy are important for the future of immunotherapy",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}